EUVIMEDEUVIMED entdecken
Crossref

Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database

Thomas Samaille, Morteza Raeisi, Romain Cohen, Qian Shi, Takayuki Yoshino, John R Zalcberg, Richard Adams, Chiara Cremolini, Axel Grothey, Robert J Mayer, Benoist Chibaudel, Aimery de Gramont und 1 weitere

Clinical Colorectal Cancer · 2026

DOI: 10.1016/j.clcc.2026.05.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2026. Verfasst von Thomas Samaille und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sorbonne University, Saint-Antoine Hospital, AP-HP, Paris, France. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Liver Neoplasms, Proto-Oncogene Proteins p21(ras), Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: KRAS mutations in metastatic colorectal cancer (mCRC) are a factor of poor prognosis, partly because of associated resistance to anti-EGFR therapies. Liver metastases (LM) were also described as a factor of poor prognosis. This study aims to compare the outcomes of patients treated in third-line setting with placebo or Trifluridine/Tipiracil or regorafenib (TToR) and to assess the impact of LM and KRAS mutations on prognosis. METHODS: Data were pooled from five placebo-controlled randomized trials of the ARCAD CRC database (CORRECT, RECOURSE, CONCUR, TERRA, and J003). Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier estimates and adjusted Cox models. Interaction tests were conducted to evaluate the combined effects of LM and KRAS mutations. RESULTS: The study included 2,207 patients: 1,464 treated with TToR and 743 with placebo. A total of 73% had LM and 51% had KRAS mutations. Patients with LM had significantly lower OS and PFS compared to those without LM in both TToR (HR = 0.48 for OS; HR = 0.55 for PFS) and placebo groups (HR = 0.49 for OS; HR = 0.58 for PFS). Patients with KRAS mutations had worse OS compared to wild-type KRAS in TToR-treated patients (HR = 1.18), but not in placebo-treated patients (HR = 1.03). Interaction tests were not significant between LM and KRAS status in both TToR and placebo groups. CONCLUSIONS: In patients with refractory mCRC, LM are a major poor prognosis factor, while KRAS mutations have no clinically relevant additive impact. These results underline the importance to stratify clinical trials on liver metastases rather than on RAS status in latter lines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsLiver NeoplasmsProto-Oncogene Proteins p21(ras)Antineoplastic Combined Chemotherapy ProtocolsHumansMutationFemalePrognosisMaleMiddle AgedPyridinesRandomized Controlled Trials as TopicAgedPhenylurea CompoundsProgression-Free SurvivalThyminePyrrolidinesTrifluridineDrug CombinationsDatabases, FactualKaplan-Meier Estimate

Stichwörter der Autor:innen

KRAS mutationLiver metastasesMetastatic colorectal cancerPrognostic factorsThird-line treatment

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanPyridinestrifluridine tipiracil drug combinationPhenylurea CompoundsregorafenibThyminePyrrolidinesTrifluridineDrug Combinations

Autor:innen und Institutionen

  • Department of Medical Oncology, Sorbonne University, Saint-Antoine Hospital, AP-HP, Paris, France.
  • Statistical Unit, ARCAD Foundation, Paris, France. Electronic address: morteza.raeisi@fondationarcad.org.
  • Department of Quantitative Health Science, Mayo Clinic, Rochester, NY.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Monash University, School of Public Health and Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia.
  • Cardiff University and Velindre Cancer Centre, Cardiff, United Kingdom.

Zitieren

APA

Samaille, T., Raeisi, M., Cohen, R., Shi, Q., Yoshino, T., Zalcberg, J. R., Adams, R., Cremolini, C., Grothey, A., Mayer, R. J., Chibaudel, B., de Gramont, A., & André, T. (2026). Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2026.05.007

Vancouver

Samaille T, Raeisi M, Cohen R, Shi Q, Yoshino T, Zalcberg JR, et al. Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database. Clinical Colorectal Cancer. 2026. doi:10.1016/j.clcc.2026.05.007

BibTeX
@article{Samaille2026,
  author = {Samaille, Thomas and Raeisi, Morteza and Cohen, Romain and Shi, Qian and Yoshino, Takayuki and Zalcberg, John R and Adams, Richard and Cremolini, Chiara and Grothey, Axel and Mayer, Robert J and Chibaudel, Benoist and de Gramont, Aimery and André, Thierry},
  title = {Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database},
  journal = {Clinical Colorectal Cancer},
  year = {2026},
  doi = {10.1016/j.clcc.2026.05.007}
}
Kostenlos starten →